Takeda on Tuesday announced that it is buying Maverick Therapeutics for as much as $525 million. The deal is a small one, but for R&D chief Andrew Plump, it represents a research and development transformation playing out at the company — and the beginning of the culmination of six years’ work.

“To be honest with you, I think this year is going to be the pinnacle for me,” Plump told STAT when asked about the high point of his time at the company. “This is our inflection year, and this is when all the work that we put in to build the culture, to really create this partnership model and to build a pipeline, this is the year that we and the outside world will start to see how far we’ve come.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What’s included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Source: STATNEWS.COM

Leave a Reply

ArabicChinese (Simplified)EnglishFrenchGermanItalianJapanesePortugueseRussianSpanish

[mc4wp_form id="449"]